

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent of: **CECCHI et al.**

Patent No. **6,858,629**

Issued: **February 22, 2005**

Title: **HETEROARYLOXY PROPANOLAMINES, PREPARATION METHOD  
AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 C.F.R. § 1.322**

It has been discovered that certain errors, as specified in the attached Certificate of Correction form (Form PTO-1050), occur in the above-identified U.S. Patent.

The following errors occurred during the printing of the patent:

1. Column 7, line 67 (page 17, line 14 of the specification): “7°-78°” should read as -- 76°-78° --.
2. Column 8, line 35 (page 18, line 27 to page19, line 1 of the specification): “piperidinylamino]-[2” should read as -- piperidinylamino]-1-[2 --.

The following errors are of a clerical or typographical nature, which were not the fault of the Patent and Trademark Office:

3. Column 6, line 52 (page 14, lines 4 to 8 of the specification): please delete the duplicated paragraph: "The water-dispersible powders or granules can comprise the active ingredient as a mixture with dispersing agents, wetting agents or suspending agents, such as polyvinylpyrrolidone, and with sweeteners or flavor enhancers."
4. In Claim 22, line 42: "irritable bowel syndromey" should read as -- irritable bowel syndrome --.

It is believed that these errors warrant the issuance of a Certificate of Correction and, in accordance with 37 C.F.R. § 1.22, it is respectfully requested that a Certificate of Correction be issued and forwarded to the address below.

As some of the above errors are of a typographical or clerical nature that were not the fault of the U.S. Patent and Trademark Office, the Commissioner is hereby authorized to deduct the fee of \$100.00 required by 37 C.F.R. §1.20(a), or any additional fees that are required by this paper, or credit any overpayment to Deposit Account No. 18-1982.

Respectfully submitted,

September 21, 2007  
Date

Kelly L. Bender  
Kelly L. Bender, Reg. No. 52,610  
Attorney for Applicant

sanofi-aventis U.S. LLC  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (610) 889-8995  
Telefax (908) 231-2626

sanofi-aventis Docket No. IVD 1135 US PCT

Staple  
Here  
Only

Printer's Trim Line

UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION

PATENT NO. : 6,858,629  
DATED : February 22, 2005  
INVENTOR(s) : Cecchi et al.

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

- Column 6, line 52: please delete "The water-dispersible powders or granules can comprise the active ingredient as a mixture with dispersing agents, wetting agents or suspending agents, such as polyvinylpyrrolidone, and with sweeteners or flavor enhancers."
- Column 7, line 67: "7°-78°" should read as -- 76°-78° --.
- Column 8, line 35: "piperidinylamino]-[2" should read as -- piperidinylamino]-1-[2 --.
- Claim 22, line 42: "irritable bowel syndromey" should read as -- irritable bowel syndrome --.

Mailing Address of Sender:

Patent No. 6,858,629

Kelly L. Bender, Reg. No. 52, 610  
U.S. Patent Operations  
sanofi-aventis Inc. LLC  
Route #202-206  
P. O. Box 6800  
Bridgewater, New Jersey 08807-0800